Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

MRUSBullishCorporate Developmentsnews

High materiality9/10

Merus Scores Its First FDA Approval For Lung Cancer Drug

Dec 5, 2024, 3:49 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The approval of Bizengri could significantly enhance MRUS's revenue potential, similar to other successful oncology drugs that saw stock price surges upon approval.

AI summary

What happened, with direct paths to the underlying reporting

FDA approves MRUS's Bizengri for advanced pancreatic cancer and NSCLC. Bizengri shows 40% ORR in pancreatic adenocarcinoma, 33% in NSCLC. Approval based on eNRGy trial; confirmatory trials needed for continued use. Projected U.S. sales for Bizengri around $16.5 million with $30,000 pricing. MRUS stock fell 3.70% following FDA approval announcement.

FDA approves MRUS's Bizengri for advanced pancreatic cancer and NSCLC.
Bizengri shows 40% ORR in pancreatic adenocarcinoma, 33% in NSCLC.
Approval based on eNRGy trial; confirmatory trials needed for continued use.
Projected U.S. sales for Bizengri around $16.5 million with $30,000 pricing.
MRUS stock fell 3.70% following FDA approval announcement.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Merus Scores Its First FDA Approval For Lung Cancer Drug

Genmab Acquires Merus for $8B to Boost Cancer Drug Pipeline

US FDA approves Merus' therapy to treat lung, pancreatic cancers